Latest news and press releases about Immuneering Corporation (IMRX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations.
Price
| Price | $4.45 |
| Market Cap | $162M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.50 |
| EV / EBITDA | -2.24 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -27.15% |
| Return on Invested Capital | -32.65% |
| Return on Assets | -28.35% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARCT · ASMB · ENTA · FHTX · HUMA · NAUT · PYXS
Explore sector: Healthcare · Biotechnology
More sections of IMRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks